Kitsa's intuitive clinical trial recruitment software helps sites screen with precision, reducing failure rates, accelerating enrollment and improving patient outcomes.
Every failed screen wastes time, drains staff, and reduces site revenue.
Sponsors lose $1,200 for every failed screen
CRCs spend hours manually reviewing mismatched records
Inaccurate screening delays enrollment and stifles growth
How clinical trial Software is helping trial sites evolve
High screening failure rates are rooted in flawed processes and outdated technology:
Screening relies on 4-5 broad criteria instead of 50+
Manual reviews create fatigue and inconsistency
Unstructured data (PDFs, notes) gets ignored
No referral networks = eligible patients missed
No traceability or audit trail for selection decisions
Traditional clinical trial solutions and tools fall short because they:
Use keyword-only filters with no true context
Can't handle complex patient data from EHRs or scanned docs
Provide no inferencing, explainability, or traceability
Don't integrate seamlessly with site workflows
Require high setup fees and a long onboarding
Offer no support for trial diversity or referrals
Kitsa is not just a screening tool—it's an AI-powered clinical trial solution purpose-built to help sites recruit the right patients faster and reduce costly screening errors.
Advanced inferencing (language, medical, and math-based)
Explainable AI: Know why each patient was selected
Full traceability to patient vitals, medications, and visit summaries
Converts unstructured data into actionable insights
Compliant patient referral sharing with your current EHR
Built-in sponsor visibilitythrough Kitsa Marketplace
EHR integration with one-click setup
Designed to simplify clinical trial site management
in additional site revenue annually
reduction in screening failures
more patients recruited per trial site
of manual effort saved per trial
faster trial completion for Sponsors
"Kitsa transformed our patient recruitment model. We saw an immediate increase
in revenue of $2.25M and quickly reduced our screening failures."
-Clinical Research Philadelphia
